12:00 AM
 | 
May 07, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

SCIB1: Phase II started

Scancell began the Phase II portion of an open-label, U.K. Phase I/II trial to evaluate 4 mg SCIB1 administered at weeks 0, 3, 6, 12 and 24 in about 13 patients with stage...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >